[1] WOOD K J, BUSHELL A, JONES N D. Immunologic unresponsiveness to alloantigen in vivo: a role for regulatory T cells ［J］. Immunol Rev, 2011, 241(1): 119-132.

[2] BRUSKO T M, PUTNAM A L, BLUESTONE J A. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities ［J］. Immunol Rev, 2008, 223: 371-390.

[3] SAKAGUCHI S, SAKAGUCHI N, ASANO M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases ［J］. J Immunol, 1995, 155(3): 1151-1164.

[4] KIM E H, BIRD J A, KULIS M, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization ［J］. J Allergy Clin Immunol, 2011, 127(3): 640-651.

[5] ZHANG, X, HUANG H, HAN S, et al. Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review ［J］. Transpl Immunol, 2012, 27(2-3): 63-68.

[6] ROLDAN C, MIRABET S, CECILIA C, et al. CD4+CD45RO+CD25-/lowCD127+: CD4+CD45RO+CD25hiCD127- /low ratio in peripheral blood&colon: a useful biomarker to detect cardiac allograft vasculopathy in heart transplanted patients ［J］. Transplantation, 2015, 99(7): 1521-1528.

[7] TSANG J Y, TANRIVER Y, JIANG S, et al. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice ［J］. J Clin Invest, 2008, 118(11): 3619-3628.

[8] SAGOO P, ALI N, GARG G, et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells ［J］. Sci Transl Med, 2011, 3(83): 83ra42.

[9] XIAO F, MA L, ZHAO M, et al. Ex vivo expanded human regulatory T cells delay islet allograft rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2r gamma (null) mice ［J］. PLoS One, 2014, 9(3): e90387.

[10] YI S, JI M, WU J, et al. Adoptive transfer with in vitro expanded human regulatory T cells protects against porcine islet xenograft rejection via interleukin-10 in humanized mice ［J］. Diabetes, 2012, 61(5): 1180-1191.

[11] WING K, ONISHI Y, PRIETO-MARTIN P, et al. CTLA-4 control over Foxp3+ regulatory T cell function ［J］. Science, 2008, 322(5899): 271-275.

[12] HACHULLA E. What’s new in internal medicine: emerging treatments for systemic lupus erythematosus ［J］. Ann Dermatol Venereol, 2011, 138(Suppl 4): S241-244.

[13] KRUMMEY S M, FORD M L. New insights into T-cell cosignaling in allograft rejection and survival ［J］. Curr Opin Organ Transplant, 2015, 20(1): 43-48.

[14] MIYARA M, YOSHIOKA Y, KITOH A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor ［J］. Immunity, 2009, 30(6): 899-911.

[15] SOJKA D K, HUGHSON A, FOWELL D J. CTLA-4 is required by CD4+CD25+ Treg to control CD4+ T-cell lymphopenia-induced proliferation ［J］. Eur J Immunol, 2009, 39(6): 1544-1551.

[16] WELLCOME TRUST CASE CONTROL CONSORTIUM. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls ［J］. Nature, 2007, 447(7145): 661-678.

[17] ZHENG Y, MANZOTTI C N, BURKE F, et al. Acquisition of suppressive function by activated human CD4+ CD25- T cells is associated with the expression of CTLA-4 not FoxP3 ［J］. J Immunoy: 1683-1691.